Study of two drugs with chemo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with metastatic colorectal cancer that has spread to other parts of the body.
- You have not had any chemotherapy or other treatment for your cancer that has spread.
- You should be in fairly good health, able to care for yourself and up and about more than half of the day.
- You do not have certain genetic subtypes of colorectal cancer (MSI-H, dMMR, or BRAF V600E mutation).
- You do not currently have a bowel blockage or significant fluid in the belly that needed draining in the last month.
- You do not have a history of inflammatory bowel disease (like Crohn's or ulcerative colitis) or ongoing chronic diarrhea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a targeted therapy) and alternating chemotherapy regimens as a first treatment for advanced colorectal cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
This study tests a combination of several cancer drugs (irinotecan, capecitabine, bevacizumab, and camrelizumab) in people with metastatic colorectal cancer who have already tried at least one prior treatment. The goal is to see if these drugs work better together for patients who don't have certain genetic features.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people whose colorectal cancer has spread to other parts of the body but not to the liver. The goal is to see if this combination works better than current treatments for this specific type of cancer.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.